

Is Besifloxacin (Besivance) in shortage in 2026? Get the latest update on availability, pricing, and what patients can do to find this eye antibiotic.
If you've had trouble filling a prescription for Besifloxacin eye drops (brand name Besivance), you may be wondering: is there a shortage? The situation with Besifloxacin in 2026 is nuanced — it's not a straightforward drug shortage like those you might see on the FDA's official list, but patients are still experiencing real difficulty getting their hands on this medication.
Here's what you need to know about the current state of Besifloxacin availability, why it might feel like a shortage, and what your options are.
As of early 2026, Besifloxacin is not listed on the FDA's official drug shortage database. This means the manufacturer, Bausch + Lomb, has not reported a production interruption or supply issue to the FDA. However, many patients report that their local pharmacies don't carry Besivance or are temporarily unable to order it.
This disconnect — where a drug isn't officially in shortage but is still hard to find — is common for brand-only specialty medications. The issue isn't that Besifloxacin isn't being manufactured; it's that many pharmacies simply don't stock it.
Several factors contribute to the practical difficulty of finding Besifloxacin:
Besifloxacin has no generic equivalent. Bausch + Lomb holds patents on Besivance that extend through November 2030, meaning no other manufacturer can produce a generic version for several more years. This single-source status means the entire U.S. supply depends on one company.
A single 5 mL bottle of Besivance costs approximately $230 to $350 at retail price without insurance. This high cost discourages pharmacies — particularly smaller ones — from keeping it on the shelf. When pharmacies do stock it and it doesn't sell quickly, they lose money on expired inventory.
Many insurance plans require prior authorization for Besivance because cheaper generic fluoroquinolone alternatives exist. Step therapy requirements may also mandate that patients try lower-cost options like generic moxifloxacin or ofloxacin before insurance will cover Besifloxacin. These barriers reduce the number of prescriptions filled, which further reduces pharmacy incentive to stock it.
Even when Besivance is being manufactured, distributor-level inventory can fluctuate. Pharmacies may find that their wholesaler is temporarily out of stock, creating localized availability gaps that look and feel like a shortage to patients.
Without insurance or a discount program, expect to pay:
For a detailed breakdown of savings options, see our guide on how to save money on Besifloxacin in 2026.
While no new formulations of Besifloxacin have been released, patients do have expanding options:
If you need Besifloxacin and your pharmacy doesn't have it, here's a step-by-step approach:
For more detailed strategies, read our comprehensive guide on how to find Besifloxacin in stock near you.
While Besifloxacin isn't in a formal FDA-recognized shortage in 2026, the practical challenges of finding it are real. The combination of brand-only status, high cost, insurance hurdles, and limited pharmacy stocking creates a situation where patients often need to take extra steps to fill their prescription.
The most important thing is to not delay your treatment. Bacterial conjunctivitis can worsen without antibiotics, and whether you fill your Besifloxacin prescription or switch to an alternative, starting therapy quickly gives you the best outcome. Use tools like Medfinder, explore savings programs, and stay in close communication with your doctor.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.